NEXENTIS TECHNOLOGIES INC. Deferred Tax Assets, Deferred Gain on Sale Leaseback Transaction
NEXENTIS TECHNOLOGIES INC. (NXTS) had Deferred Tax Assets, Deferred Gain on Sale Leaseback Transaction of $29.61 thousand as of 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes
us-gaap:DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction · last filed 2022-03-31
- 2021-12-31: Deferred Tax Assets, Deferred Gain on Sale Leaseback Transaction $29.61K.
| Period end | Deferred Tax Assets, Deferred Gain on Sale Leaseback Transaction |
|---|---|
| 2021-12-31 | $29.61K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |